Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
A subsidiary of Otsuka Holdings, focused on developing and commercializing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a new pill quiet the mind? a large trial puts it to the test
Disease control Recruiting nowThis phase 3 trial is testing whether an experimental oral medication called SEP-363856 (ulotaront) can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive one of two fixed doses of the drug or a placebo for 8 weeks. The main goal is to …
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Hope for kids with rare kidney disease: drug trial aims to slow damage
Disease control Recruiting nowThis trial tests the safety of tolvaptan, a drug that helps the body remove extra water, in 20 children aged 28 days to 18 years with autosomal recessive polycystic kidney disease (ARPKD). The goal is to see if the drug can slow kidney function decline and reduce the need for dia…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to tame rare kidney disorder that makes patients drink constantly
Disease control Recruiting nowThis early-stage trial tests a daily capsule called NDI-5001 in 24 adult men with a rare inherited kidney condition (X-linked congenital nephrogenic diabetes insipidus) that causes extreme thirst and frequent urination. The study's main goal is to check the drug's safety and how …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New schizophrenia pill shows promise in major trial
Disease control Recruiting nowThis study tests a new drug called Ulotaront (SEP-363856) to see if it can reduce symptoms like hallucinations and delusions in people with schizophrenia. About 522 adults experiencing an acute episode will receive either the drug or a placebo for 6 weeks. The main goal is to mea…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill could help control PKU – phase 3 trial now recruiting
Disease control Recruiting nowThis study tests an experimental oral drug, JNT-517, for adults with phenylketonuria (PKU), a genetic condition that causes harmful buildup of phenylalanine (Phe). About 120 adults will receive either JNT-517 or a placebo for 6 weeks, then all will receive JNT-517 for nearly a ye…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New TB drug could cut treatment time by two months
Disease control Recruiting nowThis study tests whether a new drug called quabodepistat can shorten treatment for drug-resistant tuberculosis (TB) from 6 months to 4 months. About 532 adults and teens with rifampicin-resistant or multidrug-resistant TB will be randomly assigned to receive either the new shorte…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New PKU drug JNT-517 moves to Long-Term safety trial
Disease control Recruiting nowThis Phase 3 study is testing the long-term safety of an oral drug called JNT-517 in 240 children and adults with phenylketonuria (PKU). All participants will receive the drug twice daily, with doses based on age and weight. The goal is to see if JNT-517 is safe to use over time …
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug interaction study launches for repinatrabit
Knowledge-focused Recruiting nowThis early-stage trial is testing how the experimental drug repinatrabit interacts with several common medications, including birth control pills, metformin, and methotrexate. The study involves 48 healthy volunteers and will measure drug levels in the blood to see if combining t…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Study aims to tailor PKU drug dosing for patients with organ impairment
Knowledge-focused Recruiting nowThis study looks at how the body processes repinatrabit (JNT-517), an oral tablet for phenylketonuria, in people with moderate liver impairment or severe kidney impairment. It compares these results to those from healthy volunteers of similar age, weight, and sex. The goal is to …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Brain scan study tests new Drug's target binding in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study involves 18 healthy men to see how well the experimental drug MSP-2020 attaches to serotonin receptors in the brain. Researchers will also measure how much drug stays in the blood and check for side effects. The goal is to understand the drug's activity in …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC